QSAM Biosciences, Inc. (QSAM) Research

Based in Austin, Texas, QSAM Biosciences, Inc. is dedicated to advancing nuclear medicine for cancer and related illnesses. A key component of their pipeline is CycloSam (Samarium-153 DOTMP), a radiopharmaceutical currently in clinical development that specifically targets bone. The company holds a licensing agreement with IGL Pharma, Inc. Founded in 2004, the organization operated as Q2Earth, Inc. before rebranding to QSAM Biosciences, Inc. in September 2020.

Market snapshot

Symbol
QSAM
Price
$8.30
Day change
-99.95%
Market cap
$18.4K
P/E ratio
-6.67x
52-week range
4.1-16600.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Hempfusion Wellness Inc. (CBDHF)
  • Cantabio Pharmaceuticals, Inc. (CTBO)
  • Diagnocure, Inc. (DGCRF)
  • Generex Biotechnology Corporation (GNBT)
  • Humanigen, Inc. (HGENQ)
  • Navidea Biopharmaceuticals, Inc. (NAVB)
  • NutraLife BioSciences, Inc. (NLBS)
  • NeonMind Biosciences Inc. (NMDBF)

Recent insider activity

  • Piazza C Richard — D-Return (188 shares) on 2024-05-02
  • Baum Douglas R — D-Return (188 shares) on 2024-05-02
  • Nelson Christopher M. — D-Return (91 shares) on 2024-05-02
  • Link Jr. Charles J — D-Return (41 shares) on 2024-05-02
  • Sax Adriann — D-Return (5 shares) on 2024-05-02

Open QSAM Biosciences, Inc. (QSAM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.